Introduction
============

Laryngeal cancer is a relatively common malignant tumor occurring in the head and neck regions and is responsible for \~1% of all cancer-related deaths.[@b1-ott-11-7947] A study by the National Central Cancer Registry of China showed that \~26,400 new laryngeal cancer cases occurred and resulted in 14,500 cancer-related deaths in China in 2015, and its incidence and mortality have been increasing in recent years.[@b2-ott-11-7947] Approximately 60% of the laryngeal cancer patients presented with advanced (stage III or IV) disease at diagnosis.[@b3-ott-11-7947] These patients typically suffered from dysphonia, dyspnea, and even dysphagia, which might cause serious psychological disorders and severely affect patient's quality of life.[@b4-ott-11-7947]

Currently, for most of the T3 laryngeal squamous cell carcinoma (LSCC) patients, chemoradiotherapy/radiotherapy or partial laryngectomy might be options for the preservation of laryngeal function, but most of these patients undergo total laryngectomy (TL) for various reasons. TL procedure, however, is not the best therapeutic choice in that patients' speech and physiological airway cannot be preserved due to the loss of organ, and it also causes great pain and inconvenience. Therefore, supracricoid partial laryngectomy (SCPL) is an alternative choice for some patients with advanced laryngeal cancer to avoid the TL surgery and its side effects.[@b5-ott-11-7947]--[@b7-ott-11-7947] Nevertheless, in the clinical practice, it is difficult for a surgeon to balance the benefit and risk between complete excision of the lesion and preservation of laryngeal function.

In this study, therefore, we performed a matched-pair analysis in the patients with T3 LSCC to compare survival outcomes of SCPL and TL surgical procedures. To our knowledge, this is the first study to perform a matched-pair design controlling for variables of known prognostic significance.

Patients and methods
====================

Patient population
------------------

A total of 877 patients with newly diagnosed, pathologically confirmed, and untreated T3 LSCC were enrolled into this study at the Peking Union Medical College Hospital (PUMCH) from January 1995 to December 2011. Epidemiologic and clinical information including age, sex, comorbidity score, tobacco and alcohol consumption, tumor site, overall stage, nodal stage, adjuvant treatment and grade of differentiation were obtained from the participants for this matched-pair analysis. TNM stages were identified in all participants following the TNM classification criteria designated by the American Joint Committee on Cancer (AJCC) in 2010. For the purpose of matched-pair analysis, only the patients who were eligible for either SCPL or TL were enrolled into this study in order to compare the clinical outcomes of these two surgical procedures.

"Smokers" were defined as those who had smoked \>100 cigarettes in their lifetime, whereas "non-smokers" had smoked 100 cigarettes or fewer. "Drinkers" were defined as patients who drank alcoholic beverages at least once a week for 1 year or longer; otherwise, they were defined as "non-drinkers".[@b8-ott-11-7947] A signed written informed consent form for this study was obtained from each participant, and the study protocol was approved by the ethics committee of the PUMCH.

The inclusion criteria were as follows: 1) newly diagnosed, previously untreated, and pathologically confirmed LSCCs; 2) T3 stage originating at anterior two-thirds of the larynx with true vocal cord fixation and/or paraglottic/preepiglottic space invasion without arytenoid cartilage fixation and cricoid cartilage invasion, which were eligible for either treatment modalities; and 3) patients without resection margins, perineural invasion, or extracapsular nodal spread. The exclusion criteria were as follows: 1) cases had no clear medical documentation or were lost during follow-up; 2) cases had a history of other tumors or tumor-related diseases; and 3) cases had distant metastasis.

Matching criteria
-----------------

In the current cohort study, one-to-one match was paired for the patients treated with SCPL or TL surgical procedures. The matching variables were influencing factors including age (±5 years), gender (male or female), smoking status (nonsmoker or smoker), site of primary tumor (supraglottis or glottis), disease stage (stage III or stage IV), and adjuvant treatment (untreated or radiation treated). Unmatched variables included comorbidity score (none and mild or moderate and severe), alcohol status (nondrinker or drinker), nodal classification (N0, N1, N2, or N3), and grade of differentiation (highly differentiated, moderately differentiated, or poorly differentiated). By the definition of aforementioned inclusion and exclusion criteria, total 106 pairs of (212) patients with T3 LSCC treated with SCPL or TL were finally included in this matched-pair analysis.

Surgical procedures
-------------------

The surgical operations were performed according to the original description of the techniques in the literature.[@b5-ott-11-7947],[@b9-ott-11-7947] The SCPL was classified according to the type of reconstruction: cricohyoidoepiglottopexy (CHEP) and cricohyoidopexy (CHP). It included the removal of the whole thyroid cartilage, both true and false cords, the ventricles, the epiglottis, and the paraglottic and preepiglottic spaces, meanwhile, sparing only the cricoid cartilage, hyoid bone, and at least one functional and mobile arytenoid.[@b10-ott-11-7947]

Selective neck dissections were performed in the cases with clinically positive nodules. Elective dissections were performed in cN0 of the cases with nodular metastasis, with removal of levels II--IV, sometimes including level V, according to the international guidelines. All surgical procedures were performed by the same team of surgeons to ensure comparability between the treatment groups.

Patient's follow-up
-------------------

The primary end point was overall survival (OS), defined as the time from the date of starting treatment to the date of death from any cause or last follow-up date. Secondary end points were disease-specific survival (DSS), defined as the time from the date of starting treatment to the date of death from disease or last follow-up, and recurrence-free survival (RFS), defined as the time from the date of starting treatment to the date of recurrence or date of last follow-up. Patients were followed up from the date of surgery with regularly scheduled clinical and radiographic examinations. Patients were considered alive and free of disease recurrence if disease absence was documented on the date of the last visit in December 2016. All patients were followed up for a minimum of 5 years or until death.

Statistical analyses
--------------------

Data were analyzed using SPSS (SPSS for Windows version 21.0; IBM Corporation, Armonk, NY, USA). Differences between the SCPL and TL groups in DSS, RFS, and OS were compared using the Kaplan--Meier method and the log-rank test for equality of survival curves. The multivariate analysis was performed using the Cox proportional hazards model. Factors that were not matched (comorbidity score, alcohol consumption, nodal classification, and grade of differentiation) were evaluated using the Pearson chi-squared test and the two-tailed Fisher's exact test to detect any significant differences between the SCPL and TL groups. All statistical tests were two tailed, and *P*-values \<0.05 were considered as statistically significant.

Results
=======

Demographics
------------

Characteristics of the two matched groups are presented in [Table 1](#t1-ott-11-7947){ref-type="table"}. The patients were matched by age, sex, smoking history, site of primary tumor, disease stage, and adjuvant treatment. As expected, there were no significant differences between the two groups in terms of the matching variables. Furthermore, we compared the differences in survival by each characteristic, observing significant differences in age, smoking status, tumor stage, adjuvant treatment, and histopathologic grade (*P*\<0.05 for each).

Comparison of survival rate
---------------------------

Patients were followed up at least for a minimum of 5 years or until death. The follow-up time ranged from 6 to 184 months, with an average of 72.6 months (median, 69.5 months) for the SCPL group and 84.1 months (median, 77.0 months) for the TL group.

Vital status for the patients of the two groups is listed in [Table 2](#t2-ott-11-7947){ref-type="table"}. For the SCPL group, 52 out of the 106 patients died from varying causes, 31 died from certain diseases, and 37 had recurrence. For the TL group, 61 out of the 106 patients died from varying causes, 37 died from certain diseases, and 42 had tumor recurrence. The 5-year OS rates were 65.8% and 69.8% in the SCPL and TL groups, respectively, with no significant difference between the two groups (*P*=0.41). Similar results were found for DSS (73.6% vs 77.2%, respectively, at 5 years; *P*=0.43) and RFS (72.1% vs 71.6%, respectively, at 5 years; *P*=0.66) between the two groups. Furthermore, curves of OS, DSS, and RFS in the SCPL and TL groups are shown in [Figures 1](#f1-ott-11-7947){ref-type="fig"}[](#f2-ott-11-7947){ref-type="fig"}--[3](#f3-ott-11-7947){ref-type="fig"}, respectively. None of OS, DSS, or RFS was significantly different between the SCPL and TL groups (*P*=0.47, *P*=0.66, and *P*=0.77, respectively).

Matched-pair analysis
---------------------

If a pair of the patients experienced the same events, they were classified as concordant; in contrast, if one patient of a pair experienced an event but the other one did not, they were considered as discordant.[@b11-ott-11-7947] By this definition, in this study, there were 39 concordant pairs in which both the SCPL and TL patients died from all kinds of causes; in the 13 discordant pairs, the SCPL patients died, but the TL patients did not; in the other 22 discordant pairs, the TL patients died, but the SCPL patients did not. There was no significant difference in the risk of overall death between the two treatment groups (hazard risk \[HR\]=1.15; 95% CI: 0.79--1.67; *P*=0.47; [Table 3](#t3-ott-11-7947){ref-type="table"}).

In the 17 concordant pairs, both the SCPL and TL patients died from the disease. While in the 14 discordant pairs, the SCPL patients died from the disease, but the TL patients did not; and in the other 20 discordant pairs, the TL patients died from the disease, but the SCPL patients did not. There was no significant difference in risk of death caused by the disease (HR=1.11; 95% CI: 0.69--1.80; *P*=0.66; [Table 3](#t3-ott-11-7947){ref-type="table"}).

Similarly, both the SCPL and TL patients exhibited disease recurrence in the 18 concordant pairs; while in the 19 discordant pairs, the SCPL patients exhibited disease recurrence, but the TL patients did not; and in the other 24 discordant pairs, the TL patients exhibited disease recurrence, but the SCPL patients did not. Again, no evidence of a significant difference in disease recurrence between these two groups was found (HR=1.07; 95% CI: 0.68--1.68; *P*=0.77; [Table 3](#t3-ott-11-7947){ref-type="table"}). Furthermore, multivariate analysis was performed for the unmatched factors, including comorbidity score, alcohol status, nodal classification, and differentiation grade, and there were no significant differences in OS, DSS, and RFS between the SCPL and TL groups ([Table 3](#t3-ott-11-7947){ref-type="table"}).

Discussion
==========

Optimal treatment for the patients with T3 laryngeal carcinoma remains controversial. According to the recommendations by the National Comprehensive Cancer Network (NCCN), radiotherapy (with or without chemotherapy for organ preservation) is one of the treatment options. In addition, surgical management, including TL, continues to be useful for the patients who are not suitable for chemoradiotherapy, either due to the tumor characteristics (bulky tumors or tumors combined with cartilage destruction) or the patients' general or socioeconomic conditions.[@b10-ott-11-7947] Considering a permanent tracheostoma and loss of natural voice resulted from organ's loss following TL surgery; organ-protective surgeries are important for the patients with T3 LSCC. Therefore, SCPL has recently been widely used at an increasing number of centers to improve quality of life in certain patients with advanced laryngeal cancer.[@b12-ott-11-7947]

SCPL was first described by Majer and Rieder[@b13-ott-11-7947] in 1959 and was modified by Piquet et al[@b14-ott-11-7947] in 1974. Since then, numerous studies have demonstrated that reliable therapeutic and acceptable functional results have been archived using this procedure. Especially, SCPL has widely been used in Europe for the tumors involving the glottis or supraglottis without extra-laryngeal extension staged as T3 in order to preserve the laryngeal function.[@b15-ott-11-7947]--[@b18-ott-11-7947]

The goal of the surgery for LSCC is to completely remove the tumor while maximizing the retention or reconstruction of the pronunciation, breathing, and swallowing functions;[@b19-ott-11-7947]--[@b21-ott-11-7947] thus, the surgical approach has been evolving from TL to organ preservation. A study conducted by Weinstein et al[@b22-ott-11-7947] reported that the quality of life in patients with SCPL was superior to that of patients who underwent TL with tracheoesophageal puncture and that the histological assessment of whole organ sections of TL specimens indicated that many patients who had been subjected to TL might have been candidates for SCPL.

Few studies have reported to compare the outcomes between SCPL and TL in T3 LSCC, although the oncological results of SCPL as a primary treatment have been documented in the literature.[@b23-ott-11-7947],[@b24-ott-11-7947] Lima et al have reported a 5-year DSS of 78% and a 5-year RFS of 83% in 43 patients treated with SCPL-CHEP.[@b25-ott-11-7947] Mercante et al[@b18-ott-11-7947] have reported a 5-year disease-free survival and OS of 78.2% and 87.3%, respectively, in T3 LSCC. In another study of 83 cases by De Virgilio et al, when TL was compared with SCPL-CHP among cT3 patients, a 3-year OS of 82% vs 64% and a DSS of 92% vs 73%, respectively, were reported.[@b12-ott-11-7947] Recently, Spriano et al reported that supracricoid laryngectomy by a lateral approach is feasible and safe,[@b18-ott-11-7947] and most recently, Mannelli et al performed meta-analysis on the outcomes of two conservative treatments for advanced T3--T4 laryngeal cancer.[@b26-ott-11-7947] They reported that the oncologic outcomes of transoral laser and open partial laryngectomies for advanced T3--T4 squamous cell laryngeal cancers were similar.[@b26-ott-11-7947]

In the current study, we matched 106 pairs of patients, who underwent SCPL or TL, using the matching variables of age, sex, smoking status, tumor site, disease stage, and adjuvant treatment. All cases were strictly limited to those with endolaryngeal invasive squamous cell carcinoma classified as T3 and were eligible for either treatment modalities with a minimum of 5 years of follow-up or longer up to death. Patients were informed on potential advantages and disadvantages of the two different treatment options, and treatment selection was mainly based on the patients' general condition and their subjective preferences. Patients with severe COPD and impairment of the cough reflex were considered unsuitable for SCPL. To the best of our knowledge, this matched-pair analysis was the only study thus far that compared TL and SCPL as primary surgical treatments in terms of survival in patients with LSCC classified as T3.

In the TL group, 5-year OS and DSS rates were 69.8% and 77.2%, respectively. As expected, comparable results (65.8% and 73.6%, respectively) were also achieved in the SCPL treatment group, as evidenced by the absence of significant differences between the two groups. In fact, SCPL resulted in slightly better 5-year RFS rates than TL (72.1% vs 71.6%, respectively), but no significant difference was found between the two groups. These findings were similar to those reported in the previous studies, although the rates of the current study were slightly lower. Potential reason of the difference in the rates might be that regional advanced stage (N2--N3) cases were predominated in this study.

It has been consistently reported that N stage is the most predictive characteristic of survival.[@b27-ott-11-7947] Owing to the risk of occult nodal metastasis in T3, all the patients of this study received neck dissection and no patient experienced regional failure or complications related to neck dissection. This procedural policy allowed us to document the exact number of affected lymph nodes and the presence of extracapsular nodal spread and enabled us to choose the best adjuvant treatment for each patient. As a result, the percentage of pathological nodes that were classified as N2--N3 stage was 46.2%, and we believed that this might be due to the high proportion (38.7%) of supraglottic cancer, which was included in this study and theoretically had a higher incidence of lymph node metastasis.

Possibility of the bias for patient selection was one of the limitations of this study as it was a single hospital-based retrospective study. Second, a relatively small sample size (106 pairs) was also a potential limitation. Nevertheless, given the OS and follow-up times of this study, we had 80% power for detecting a minimal 1.6-fold increased risk of recurrence or death in the study groups. Finally, other potentially important data, such as human papillomavirus status, which were recently documented as a predictor of laryngeal cancer[@b28-ott-11-7947] and socioeconomic or marital status were not included in this study. These remained to be collected in the future larger studies to further validate the current findings.

Conclusion
==========

No evidence of significant differences in OS, DSS, or RFS between the two surgical procedures of SCPL and TL used in the T3 LSCC patients was found when they were match paired by age, sex, smoking status, tumor site, disease stage, and adjuvant treatment. Findings of the current study suggested that SCPL has reliable therapeutic and functional outcomes for locally advanced tumors and might be used to avoid a TL in selected patients with advanced stage primary laryngeal cancer.
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###### 

Matched, demographic, and exposure characteristics

  Variable                                                         SCPL (n=106)   TL (n=106)   Log-rank *P*-value          
  ---------------------------------------------------------------- -------------- ------------ -------------------- ------ ---------
                                                                                                                           
  Age[\*](#tfn1-ott-11-7947){ref-type="table-fn"}, years                                       0.009                       
   Mean                                                            58.7           59.9                                     
   Median                                                          57             61                                       
   Range                                                           34--70         32--75                                   
                                                                                                                           
  Sex[\*](#tfn1-ott-11-7947){ref-type="table-fn"}                                                                          0.571
   Male                                                            96             90.6         96                   90.6   
   Female                                                          10             9.4          10                   9.4    
                                                                                                                           
  Adult comorbidity score                                                                                                  0.558
   None and mild                                                   100            94.3         94                   88.7   
   Moderate and severe                                             6              5.7          12                   11.3   
                                                                                                                           
  Smoking status[\*](#tfn1-ott-11-7947){ref-type="table-fn"}                                                               0.021
   Smokers                                                         87             82.1         87                   82.1   
   Nonsmokers                                                      19             17.9         19                   17.9   
                                                                                                                           
  Alcohol                                                                                                                  0.516
   Drinkers                                                        82             77.4         88                   83.0   
   Non-drinkers                                                    24             22.6         18                   17.0   
                                                                                                                           
  Tumor site[\*](#tfn1-ott-11-7947){ref-type="table-fn"}                                                                   0.766
   Supraglottis                                                    41             38.7         41                   38.7   
   Glottis                                                         65             61.3         65                   61.3   
                                                                                                                           
  Stage[\*](#tfn1-ott-11-7947){ref-type="table-fn"}                                                                        \<0.001
   III                                                             57             53.8         57                   53.8   
   IV                                                              49             46.2         49                   46.2   
                                                                                                                           
  Adjuvant treatment[\*](#tfn1-ott-11-7947){ref-type="table-fn"}                                                           \<0.001
   Untreated                                                       57             53.8         57                   53.8   
   Radiation                                                       49             46.2         49                   46.2   
                                                                                                                           
  Grade                                                                                                                    \<0.001
   Highly differentiated                                           23             21.7         19                   17.9   
   Moderately differentiated                                       65             61.3         67                   63.2   
   Poorly differentiated                                           18             17.0         20                   18.9   

**Note:**

Matched variables: age, sex, smoking status, tumor site, stage, and adjuvant treatment.

**Abbreviations:** SCPL, supracricoid partial laryngectomy; TL, total laryngectomy.

###### 

Follow-up outcomes in the two groups

  Vital status              SCPL (n=106)   TL (n=106)        
  ------------------------- -------------- ------------ ---- ------
                                                             
  Death, all causes                                          
   No                       54             50.9         45   42.5
   Yes                      52             49.1         61   57.5
                                                             
  Death, due to a disease                                    
   No                       75             70.8         69   65.1
   Yes                      31             29.2         37   34.9
                                                             
  Recurrence                                                 
   No                       69             65.1         64   60.4
   Yes                      37             34.9         42   39.6

**Abbreviations:** SCPL, supracricoid partial laryngectomy; TL, total laryngectomy.

###### 

Risks associated with different surgical procedures

                            Risk, SCPL to TL   Adjusted risk, SCPL to TL                              
  ------------------------- ------------------ --------------------------- ------------ ------ ------ ------------
                                                                                                      
  Death, all cause          1.15               0.47                        0.79--1.67   1.31   0.18   0.89--1.95
                                                                                                      
  Death, due to a disease   1.11               0.66                        0.69--1.80   1.36   0.24   0.81--2.28
                                                                                                      
  Recurrence                1.07               0.77                        0.68--1.68   1.33   0.25   0.82--2.15

**Abbreviations:** SCPL, supracricoid partial laryngectomy; TL, total laryngectomy; HR, hazard risk.
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